Products
Podentamig Biosimilar Trispecific Antibody (BCMA × CD3 × Albumin) for Research
Cat No.: GMP-Bios-INN-1337
Anti-TNFRSF17/BCM/BCMA/CD269/TNFRSF13A therapeutic antibody (Pre-made Podentamig biosimilar,Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Podentamig (development code HPN-217) is a trispecific antibody targeting BCMA (TNFRSF17); albumin. It is developed by Harpoon Therapeutics for Multiple myeloma in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1337-1mg | 1mg | |
| GMP-Bios-INN-1337-10mg | 10mg | |
| GMP-Bios-INN-1337-100mg | 100mg | |
| GMP-Bios-INN-1337-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Podentamig biosimilar, Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl), Anti-TNFRSF17/BCM/BCMA/CD269/TNFRSF13A;ALB;CD3E Antibody: Anti-TNFRSF17/BCMA/CD269/Tumor necrosis factor receptor superfamily member 17 therapeutic antibody |
| INN Name | Podentamig |
| Target | TNFRSF17/BCM/BCMA/CD269/TNFRSF13A;ALB;CD3E |
| Format | Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl); Bispecific entry |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;na |
| VD LC | na;na |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;8z8v:B |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Harpoon Therapeutics |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
